| 000 | 01588 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250515173114.0 | ||
| 264 | 0 | _c20091117 | |
| 008 | 200911s 0 0 eng d | ||
| 022 | _a1365-2893 | ||
| 024 | 7 |
_a10.1111/j.1365-2893.2009.01122.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aReddy, K R | |
| 245 | 0 | 0 |
_aPeginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. _h[electronic resource] |
| 260 |
_bJournal of viral hepatitis _cOct 2009 |
||
| 300 |
_a724-31 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHepacivirus _xclassification |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xadministration & dosage |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 |
_aRibavirin _xadministration & dosage |
| 650 | 0 | 4 | _aSecondary Prevention |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMessinger, D | |
| 700 | 1 | _aPopescu, M | |
| 700 | 1 | _aHadziyannis, S J | |
| 773 | 0 |
_tJournal of viral hepatitis _gvol. 16 _gno. 10 _gp. 724-31 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2893.2009.01122.x _zAvailable from publisher's website |
| 999 |
_c18911294 _d18911294 |
||